GemmaCert develops a hardware device that enables rapid analysis of cannabis samples to support personalised and reliable dosing. The company says the device helps overcome challenges posed by heterogeneous cannabis flower and the unpredictability of cannabis effectiveness. GemmaCert plans to use new funding for recruitment and business development, with a view to hitting revenue this year. Management also intends to adapt the company’s growth in Europe to align with changing medicinal and recreational legislation. The firm highlights patient safety and consistent dosing as primary use cases for its product, per statements from its CEO and chief scientific officer. GemmaCert was founded in response to growing cannabis legalisation and is based in Israel.

Total raised

$2M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2018